CONTEXT: Marijuana smoke contains many of the same constituents as tobacco smoke, but whether it has similar adverse effects on pulmonary function is unclear. OBJECTIVE: To analyze associations between marijuana (both current and lifetime exposure) and pulmonary function. DESIGN, SETTING, AND PARTICIPANTS: The Coronary Artery Risk Development in Young Adults (CARDIA) study, a longitudinal study collecting repeated measurements of pulmonary function and smoking over 20 years (March 26, 1985-August 19, 2006) in a cohort of 5115 men and women in 4 US cities. Mixed linear modeling was used to account for individual age-based trajectories of pulmonary function and other covariates including tobacco use, which was analyzed in parallel as a positive control. Lifetime exposure to marijuana joints was expressed in joint-years, with 1 joint-year of exposure equivalent to smoking 365 joints or filled pipe bowls. MAIN OUTCOME MEASURES: Forced expiratory volume in the first second of expiration (FEV(1)) and forced vital capacity (FVC). RESULTS: Marijuana exposure was nearly as common as tobacco exposure but was mostly light (median, 2-3 episodes per month). Tobacco exposure, both current and lifetime, was linearly associated with lower FEV(1) and FVC. In contrast, the association between marijuana exposure and pulmonary function was nonlinear (P < .001): at low levels of exposure, FEV(1) increased by 13 mL/joint-year (95% CI, 6.4 to 20; P < .001) and FVC by 20 mL/joint-year (95% CI, 12 to 27; P < .001), but at higher levels of exposure, these associations leveled or even reversed. The slope for FEV(1) was -2.2 mL/joint-year (95% CI, -4.6 to 0.3; P = .08) at more than 10 joint-years and -3.2 mL per marijuana smoking episode/mo (95% CI, -5.8 to -0.6; P = .02) at more than 20 episodes/mo. With very heavy marijuana use, the net association with FEV(1) was not significantly different from baseline, and the net association with FVC remained significantly greater than baseline (eg, at 20 joint-years, 76 mL [95% CI, 34 to 117]; P < .001). CONCLUSION: Occasional and low cumulative marijuana use was not associated with adverse effects on pulmonary function.
CONTEXT: Marijuana smoke contains many of the same constituents as tobacco smoke, but whether it has similar adverse effects on pulmonary function is unclear. OBJECTIVE: To analyze associations between marijuana (both current and lifetime exposure) and pulmonary function. DESIGN, SETTING, AND PARTICIPANTS: The Coronary Artery Risk Development in Young Adults (CARDIA) study, a longitudinal study collecting repeated measurements of pulmonary function and smoking over 20 years (March 26, 1985-August 19, 2006) in a cohort of 5115 men and women in 4 US cities. Mixed linear modeling was used to account for individual age-based trajectories of pulmonary function and other covariates including tobacco use, which was analyzed in parallel as a positive control. Lifetime exposure to marijuanajoints was expressed in joint-years, with 1 joint-year of exposure equivalent to smoking 365 joints or filled pipe bowls. MAIN OUTCOME MEASURES: Forced expiratory volume in the first second of expiration (FEV(1)) and forced vital capacity (FVC). RESULTS:Marijuana exposure was nearly as common as tobacco exposure but was mostly light (median, 2-3 episodes per month). Tobacco exposure, both current and lifetime, was linearly associated with lower FEV(1) and FVC. In contrast, the association between marijuana exposure and pulmonary function was nonlinear (P < .001): at low levels of exposure, FEV(1) increased by 13 mL/joint-year (95% CI, 6.4 to 20; P < .001) and FVC by 20 mL/joint-year (95% CI, 12 to 27; P < .001), but at higher levels of exposure, these associations leveled or even reversed. The slope for FEV(1) was -2.2 mL/joint-year (95% CI, -4.6 to 0.3; P = .08) at more than 10 joint-years and -3.2 mL per marijuana smoking episode/mo (95% CI, -5.8 to -0.6; P = .02) at more than 20 episodes/mo. With very heavy marijuana use, the net association with FEV(1) was not significantly different from baseline, and the net association with FVC remained significantly greater than baseline (eg, at 20 joint-years, 76 mL [95% CI, 34 to 117]; P < .001). CONCLUSION: Occasional and low cumulative marijuana use was not associated with adverse effects on pulmonary function.
Authors: Donald P Tashkin; Gayle C Baldwin; Theodore Sarafian; Steven Dubinett; Michael D Roth Journal: J Clin Pharmacol Date: 2002-11 Impact factor: 3.126
Authors: R J Hancox; R Poulton; M Ely; D Welch; D R Taylor; C R McLachlan; J M Greene; T E Moffitt; A Caspi; M R Sears Journal: Eur Respir J Date: 2009-08-13 Impact factor: 16.671
Authors: Goodarz Danaei; Eric L Ding; Dariush Mozaffarian; Ben Taylor; Jürgen Rehm; Christopher J L Murray; Majid Ezzati Journal: PLoS Med Date: 2009-04-28 Impact factor: 11.069
Authors: Joseph A Simonetti; Matthew R Gingo; Lawrence Kingsley; Cathy Kessinger; Lorrie Lucht; Gk Balasubramani; Joseph K Leader; Laurence Huang; Ruth M Greenblatt; John Dermand; Eric C Kleerup; Alison Morris Journal: J AIDS Clin Res Date: 2014-11
Authors: Madeline A Morris; Sean R Jacobson; Gregory L Kinney; Donald P Tashkin; Prescott G Woodruff; Eric A Hoffman; Richard E Kanner; Christopher B Cooper; M Brad Drummond; R Graham Barr; Elizabeth C Oelsner; Barry J Make; MeiLan K Han; Nadia N Hansel; Wanda K O'Neal; Russell P Bowler Journal: Chronic Obstr Pulm Dis Date: 2018-01-24
Authors: Benedikt Fischer; Cayley Russell; Pamela Sabioni; Wim van den Brink; Bernard Le Foll; Wayne Hall; Jürgen Rehm; Robin Room Journal: Am J Public Health Date: 2017-06-23 Impact factor: 9.308
Authors: S Grassin-Delyle; E Naline; A Buenestado; C Faisy; J-C Alvarez; H Salvator; C Abrial; C Advenier; L Zemoura; P Devillier Journal: Br J Pharmacol Date: 2014-06 Impact factor: 8.739